Cancer Monoclonal Antibodies Global Market Report 2024

Description

Cancer monoclonal antibodies are lab-created proteins designed to bind to specific targets, such as antigens on cancer cells. Each antibody is tailored to bind to a single antigen, resulting in a diverse range of monoclonal antibodies.

Key types of monoclonal antibody therapies for cancer include bevacizumab (Avastin), rituximab (Rituxan), trastuzumab (Herceptin), cetuximab (Erbitux), and panitumumab (Vectibix). Avastin, for example, is utilized for treating wet age-related macular degeneration and diabetic eye problems. Applications span breast cancer, blood cancer, liver cancer, brain cancer, colorectal cancer, and more. These therapies are utilized across various sectors, including hospitals, clinics, research laboratories, pharmacies, and others.

The cancer monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides cancer monoclonal antibodies market statistics, such as cancer monoclonal antibodies industry global market size, regional shares, competitors with a cancer monoclonal antibodies market share, detailed cancer monoclonal antibodies market segments, market trends and opportunities, and any other information you may require to thrive in the ca This cancer monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cancer monoclonal antibodies market size has grown rapidly in recent years. It will grow from $59.98 billion in 2023 to $66.1 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The historical growth can be attributed to the growth of emerging markets, a rise in research and development (R&D) expenditure, an increased geriatric population, and a growing preference for biological treatments.

The cancer monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $95.99 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. Anticipated growth in the forecast period is driven by the increasing prevalence of cancer, expanding global access, and a rise in healthcare expenditure. Key trends include product innovation through strategic collaborations, technological advancements, the development of humanized cancer monoclonal antibodies, investments in AI to reduce R&D costs and expedite drug development, and increased R&D investments.

The surge in cancer incidences worldwide is poised to significantly contribute to the expansion of the cancer monoclonal antibody market. For instance, data from the American Cancer Society projected approximately 1.9 million new cancer diagnoses and an estimated 609,360 cancer-related deaths in the United States alone in January 2022, translating to roughly 1,670 fatalities daily. Globally, the four most prevalent cancer types - lung, prostate, bowel, and female breast cancer - collectively account for 43 percent of all new cancer cases. Consequently, the escalating rates of cancer incidence on a global scale are expected to drive heightened demand within the cancer monoclonal antibody market.

The anticipated growth of the Cancer Monoclonal Antibodies market is further fueled by an upsurge in healthcare expenditures. Healthcare expenditures encompass the aggregate amount allocated toward healthcare-related services, products, and endeavors over a specified period, whether at an individual, community, national, or global level. Increased investment in healthcare sectors can substantially bolster the development, accessibility, and research pertaining to monoclonal antibody treatments. Moreover, such investments facilitate the integration of cutting-edge technologies in the production and delivery of these treatments. Notably, the Office for National Statistics reported in May 2023 that healthcare spending in the UK experienced a notable upswing, with a nominal increase of 9.4% and a real increase of 9.7%. In 2021, the UK's total healthcare expenditure amounted to $367.25 billion (£280.7 billion), with pharmaceutical expenditure reaching $51.84 billion (£39.6 billion). Additionally, preventive care spending surged to $45.93 billion (£35.1 billion) in 2021, more than doubling from the previous year. Consequently, the escalating healthcare expenditure landscape is expected to be a key driver propelling the growth trajectory of the cancer monoclonal antibodies market in the foreseeable future.

Companies within the cancer monoclonal antibody market are actively pursuing product innovation through strategic collaborations as a means to sustain competitiveness in the industry. To navigate the increasingly competitive landscape, these companies are not only focusing on developing innovative products but also engaging in partnerships aimed at sharing skills and expertise. While partnerships with academic and research institutions have been a traditional practice in this sector, the trend of collaboration has notably intensified in recent years. As an illustration, in March 2023, BioNTech SE, a German biotechnology research company, entered into a partnership with OncoC4, Inc. This collaboration aims to jointly develop and commercialize an innovative checkpoint antibody targeting various solid tumor indications. BioNTech will gain an exclusive worldwide license for the ONC-392 anti-CTLA-4 monoclonal antibody from OncoC4. The partnership outlines plans for joint development in solid tumor indications, including the initiation of a Phase 3 trial in 2023. Additionally, BioNTech will explore combination therapies and provide a $200 million upfront payment, alongside royalty payments, and potential milestone payments to OncoC4. OncoC4, Inc., based in the US, specializes in the clinical-stage development of biopharmaceuticals for cancer treatment.

Companies are directing their efforts toward pioneering biologic therapies, such as EPKINLY, to reinforce their market position. EPKINLY stands as an FDA-approved bispecific antibody designed for the treatment of advanced lymphoma. In a significant development in May 2023, AbbVie Inc., a US-based biopharmaceutical company, secured approval from the U.S. Food and Drug Administration (FDA) for EPKINLYTM (epcoritamab-bysp). This groundbreaking approval marks EPKINLY as the first and sole T-cell engaging bispecific antibody designated for treating adult patients grappling with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including instances originating from indolent lymphoma, and high-grade B-cell lymphoma (HGBL) who have undergone at least two rounds of systemic therapies.

In November 2021, Pfizer Inc., a U.S.-based pharmaceutical and biotechnology company, successfully acquired Trillium Therapeutics for $2.22 billion. This strategic acquisition is geared towards expanding Pfizer's portfolio of biologics that boost the innate immune system, targeting both hematological malignancies and solid tumors. Trillium Therapeutics, headquartered in Canada, specializes in the development of innovative immunotherapies and antibody programs for cancer treatment.

Major companies operating in the cancer monoclonal antibodies market report are F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb Company, Johnson & Johnson, Amgen Inc., AstraZeneca PLC, Eli Lilly and Company, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A, Innovent Biologics, Sino biological, Shanghai Henlius Biotech, Intas bio, Zydus Cadila, Ranbaxy, Takeda pharmaceuticals, AbbVie Inc., Biogen Idec, Bayer AG, Novartis AG, BiosanaPharma, WuXi, GlaxoSmithKline, Teva UK Limited, Abbott Laboratories, Fujifilm, Procos SpA, BSP Pharmaceuticals, Genmab, Insysbio, Rani Therapeutics, Emisphere Technologies, Inc., Enteris BioPharma, Allena Pharmaceuticals, Apotex, Gilead Sciences, Eurofarma, Teuto Brasileiro, BioMarin Pharmaceutical, BIONOVIS BRASIL, Ecopharm, Hypermarcas, Ache, Libbs Farmaceutica, Julphar, Spimaco Addwaeih, Hikma Pharmaceuticals, Tabuk, Novo Nordisk, BBI Solutions, APC Pharma, EPICIO, Medical Union Pharmaceuticals, South Egypt Drug Industries Co. Pharmaceutical, Vacsera Pharma, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd., 54gene, Baxter International, Altis Biologics, Cipla Medpro South Africa, Genzyme

North America was the largest region in the cancer monoclonal antibodies market in 2023. The regions covered in the cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The cancer monoclonal antibody market consists of sales of pembrolizumab, blinatumomab, casirivimab, and imdevimab. Values in this market are ""factory gate values,"" that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Monoclonal Antibodies Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer monoclonal antibodies? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer monoclonal antibodies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Monoclonal Antibody Therapies: Avastin; Herceptin; Keytruda; Opdivo; Darzalex; Perjeta; Others
2) By Application: Breast Cancer; Blood Cancer; Lung Cancer; Brain Tumor; Colorectal Cancer; Cervical Cancer; Gastric Cancer; Others
3) By End-User: Hospitals; Research Laboratories; Others
Companies Mentioned: F. Hoffmann-La Roche Ltd; Merck & Co., Inc; Bristol Myers Squibb Company; Johnson & Johnson; Amgen Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r14369

1. Executive Summary

2. Cancer Monoclonal Antibodies Market Characteristics

3. Cancer Monoclonal Antibodies Market Trends And Strategies

4. Cancer Monoclonal Antibodies Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Cancer Monoclonal Antibodies Market Size and Growth

5.1. Global Cancer Monoclonal Antibodies Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Cancer Monoclonal Antibodies Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Cancer Monoclonal Antibodies Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Cancer Monoclonal Antibodies Market Segmentation

6.1. Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Bevacizumab (Avastin)
Rituximab (Rituxan)
Trastuzumab (Herceptin)
Cetuximab (Erbitux)
Panitumumab (Vectibix)
Other Monoclonal Antibody Therapies
6.2. Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Breast Cancer
Blood Cancer
Liver Cancer
Brain Cancer
Colorectal Cancer
Other Applications
6.3. Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals And Clinics
Research Laboratories
Pharmacies
Other End Users

7. Cancer Monoclonal Antibodies Market Regional And Country Analysis

7.1. Global Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Cancer Monoclonal Antibodies Market

8.1. Asia-Pacific Cancer Monoclonal Antibodies Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Cancer Monoclonal Antibodies Market

9.1. China Cancer Monoclonal Antibodies Market Overview
9.2. China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Cancer Monoclonal Antibodies Market

10.1. India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Cancer Monoclonal Antibodies Market

11.1. Japan Cancer Monoclonal Antibodies Market Overview
11.2. Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Cancer Monoclonal Antibodies Market

12.1. Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Cancer Monoclonal Antibodies Market

13.1. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Cancer Monoclonal Antibodies Market

14.1. South Korea Cancer Monoclonal Antibodies Market Overview
14.2. South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Cancer Monoclonal Antibodies Market

15.1. Western Europe Cancer Monoclonal Antibodies Market Overview
15.2. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Cancer Monoclonal Antibodies Market

16.1. UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Cancer Monoclonal Antibodies Market

17.1. Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Cancer Monoclonal Antibodies Market

18.1. France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Cancer Monoclonal Antibodies Market

19.1. Italy Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Cancer Monoclonal Antibodies Market

20.1. Spain Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Cancer Monoclonal Antibodies Market

21.1. Eastern Europe Cancer Monoclonal Antibodies Market Overview
21.2. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Cancer Monoclonal Antibodies Market

22.1. Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Cancer Monoclonal Antibodies Market

23.1. North America Cancer Monoclonal Antibodies Market Overview
23.2. North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Cancer Monoclonal Antibodies Market

24.1. USA Cancer Monoclonal Antibodies Market Overview
24.2. USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Cancer Monoclonal Antibodies Market

25.1. Canada Cancer Monoclonal Antibodies Market Overview
25.2. Canada Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Cancer Monoclonal Antibodies Market

26.1. South America Cancer Monoclonal Antibodies Market Overview
26.2. South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Cancer Monoclonal Antibodies Market

27.1. Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Cancer Monoclonal Antibodies Market

28.1. Middle East Cancer Monoclonal Antibodies Market Overview
28.2. Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Cancer Monoclonal Antibodies Market

29.1. Africa Cancer Monoclonal Antibodies Market Overview
29.2. Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Cancer Monoclonal Antibodies Market Competitive Landscape And Company Profiles

30.1. Cancer Monoclonal Antibodies Market Competitive Landscape
30.2. Cancer Monoclonal Antibodies Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Ltd
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Merck & Co., Inc
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Bristol Myers Squibb Company
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Johnson & Johnson
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Amgen Inc
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Cancer Monoclonal Antibodies Market Other Major And Innovative Companies

31.1. AstraZeneca plc
31.2. Eli Lilly and Company
31.3. Pfizer Inc
31.4. Regeneron Pharmaceuticals Inc
31.5. Sanofi S.A
31.6. Innovent Biologics
31.7. Sino biological
31.8. Shanghai Henlius Biotech
31.9. Intas bio
31.10. Zydus Cadila
31.11. Ranbaxy
31.12. Takeda pharmaceuticals
31.13. AbbVie Inc
31.14. Biogen Idec
31.15. Bayer AG

32. Global Cancer Monoclonal Antibodies Market Competitive Benchmarking

33. Global Cancer Monoclonal Antibodies Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Cancer Monoclonal Antibodies Market

35. Cancer Monoclonal Antibodies Market Future Outlook and Potential Analysis

35.1 Cancer Monoclonal Antibodies Market In 2028 - Countries Offering Most New Opportunities
35.2 Cancer Monoclonal Antibodies Market In 2028 - Segments Offering Most New Opportunities
35.3 Cancer Monoclonal Antibodies Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer